Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Genentech Developed Breakthrough Therapy Gantenerumab for Alzheimer’s Disease

Genentech developed a breakthrough therapy for the treatment of patients living with early Alzheimer's disease (AD). This will be the first medicine to treat Alzheimer’s disease at-home administration.

Gantenerumab is the first investigational IgG1 antibody designed with late-stage trials for the treatment of AD. It binds the aggregated forms of amyloid beta and removes brain amyloid plaques, a pathological hallmark of Alzheimer’s disease (AD).

The pivotal GRADUATE trials carried out for gantenerumab will investigate its effects on amyloid load and downstream biomarkers of disease as well as safety and efficiency of gantenerumab early (prodromal-to-mild) AD in patients.

Alzheimer's disease (AD) is a type of brain disorder causing weaking in memory, language and other problems such as thinking skills, changes in mood and behaviour. Alzheimer's the common form of dementia and it is expected to reach disease population of 78 million by 2030 and currently affecting more than 55 million people globally. Moreover, nearly 10 million people are diagnosed with AD every year.

U.S. Food and Drug administrator has granted breakthrough therapy designation for Gantenerumab, investigational antibody for Alzheimer's disease (AD).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024